{"disease":{"id":"acellular-pertussis","name":"acellular pertussis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00148941","title":"Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4209,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00325156","title":"Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2590,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05951725","title":"A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2520,"lead_sponsor_name":"CanSino Biologics Inc.","has_results":false},{"nct_id":"NCT00346073","title":"Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2337,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00489970","title":"Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1954,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00385255","title":"Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1726,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00463437","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1437,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00282295","title":"US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1344,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00835237","title":"Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1332,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00908115","title":"Post Market Surveillance for Infanrix™","phase":"","overall_status":"COMPLETED","enrollment_count":1258,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01086423","title":"Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":985,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01449812","title":"Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":831,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01248884","title":"Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":721,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00325143","title":"Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":702,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02377349","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":688,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01929291","title":"Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":682,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01362322","title":"Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":671,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT07418372","title":"Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":660,"lead_sponsor_name":"Institute of Medical Biology, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT00412854","title":"Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":660,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01453998","title":"Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":657,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01568060","title":"Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":645,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02422264","title":"Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":601,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02096263","title":"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02853929","title":"Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":551,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00352963","title":"Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":480,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT01090453","title":"Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":480,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00871117","title":"Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":478,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00696423","title":"Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":467,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00290342","title":"Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":458,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01309646","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":454,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03311659","title":"Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":448,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00970307","title":"Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":421,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00635128","title":"Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":415,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00627458","title":"Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":403,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01171989","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":391,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01245049","title":"Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06815250","title":"Enhancing Maternal Vaccine Knowledge and Uptake: the InTroDuce-Programme Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":351,"lead_sponsor_name":"Universiti Putra Malaysia","has_results":false},{"nct_id":"NCT01577732","title":"Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":321,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00871000","title":"Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":303,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01988857","title":"Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":302,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00611559","title":"Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":283,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03824093","title":"High and Low Resource Interventions to Promote HPV Vaccines","phase":"NA","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"Children's Mercy Hospital Kansas City","has_results":false},{"nct_id":"NCT01353703","title":"Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00753649","title":"Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01323959","title":"Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":212,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00548171","title":"Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":203,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01147900","title":"Evaluation of Boostrix™10 Years After Previous Booster Vaccination","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01738477","title":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06135636","title":"Assessing Interventions to Increase Tdap Acceptance for Non-birthing Partners in Pregnancy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Women and Infants Hospital of Rhode Island","has_results":false},{"nct_id":"NCT05662852","title":"Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"ABO Holdings, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}